Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-004505-32-DE (EUCTR)	06/07/2021	25/05/2021	Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of newly diagnosed relapsing multiple sclerosis (RMS) patients	An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT-physician’s choice in the treatment of newly diagnosed RMS - STHENOS	Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclerosis relapse;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Kesimpta Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB Product Name: Glatiramer acetate INN or Proposed INN: GLATIRAMER ACETATE Other descriptive name: GLATIRAMER ACETATE Product Name: Glatiramer acetate INN or Proposed INN: GLATIRAMER ACETATE Other descriptive name: GLATIRAMER ACETATE Product Name: Interferon ß-1b INN or Proposed INN: INTERFERON BETA -1B Other descriptive name: INTERFERON BETA -1B Product Name: Interferon ß-1a INN or Proposed INN: Interferon beta -1a Product Name: Interferon ß-1a INN or Proposed INN: Interferon beta -1a Product Name: Interferon ß-1a	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	236	Phase 3	France;Spain;Germany;Italy
2	EUCTR2020-004505-32-FR (EUCTR)	09/06/2021	26/04/2021	Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of newly diagnosed relapsing multiple sclerosis (RMS) patients	An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT-physician’s choice in the treatment of newly diagnosed RMS - STHENOS	Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclerosis relapse;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Kesimpta Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB Product Name: Glatiramer acetate Other descriptive name: GLATIRAMER ACETATE Product Name: Glatiramer acetate Other descriptive name: GLATIRAMER ACETATE Product Name: Interferon ß-1b Other descriptive name: INTERFERON BETA -1B Product Name: Interferon ß-1a INN or Proposed INN: Interferon beta -1a Product Name: Interferon ß-1a INN or Proposed INN: Interferon beta -1a Product Name: Interferon ß-1a INN or Proposed INN: Interferon beta -1a	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	236	Phase 3	France;Germany
3	NCT01158183 (ClinicalTrials.gov)	July 2007	7/7/2010	Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis	Real-World Betaseron® Outcomes Study (ROBUST): A Twelve-month, US Prospective, Observational, Open-label, Single-arm, Multi-center Outcomes Study of Interferon ß-1b (Betaseron®) Given Every Other Day for Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: BAY86-5046_Interferon-beta-1b	Bayer	NULL	Completed	18 Years	65 Years	Both	226	N/A	United States
4	NCT00270816 (ClinicalTrials.gov)	November 2005	27/12/2005	Interferon ß-1b Treatment by Cyclical Administration	Effect of Cyclical Administration of Interferon ß-1b in Multiple Sclerosis - Comparison With Normal Dose.	Multiple Sclerosis	Drug: Interferon-ß-1b;Drug: Interferon ß-1b	S. Andrea Hospital	Italian Multiple Sclerosis Foundation	Completed	18 Years	55 Years	All	60	Phase 2/Phase 3	Italy